All type of patients : 2 trials - Heymsfield - XENDOS (Chiasson)
orlistat vs placebo | No demonstrated result suggested Diabetes by 57% (not demonstrated) | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
---|
normoglycemia | no data | cardiovascular events | no data | Cardiovascular death | no data | myocardial infarction (fatal and non fatal) | no data | stroke (fatal and non fatal) | no data | cardiovascular death, MI, stroke | no data | Diabetes | 0.43 [0.20 0.96] | p=0.04 | 0 | -36 | 2 | Heymsfield,XENDOS (Chiasson), | hospitalisation for heart failure | no data | All cause death | no data | TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
People with impaired glucose tolerance: 2 trials - Heymsfield - XENDOS (Chiasson)
orlistat vs placebo | No demonstrated result suggested Diabetes by 57% (not demonstrated) | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
---|
normoglycemia | no data | cardiovascular events | no data | Cardiovascular death | no data | myocardial infarction (fatal and non fatal) | no data | stroke (fatal and non fatal) | no data | cardiovascular death, MI, stroke | no data | Diabetes | 0.43 [0.20 0.96] | p=0.04 | 0 | -36 | 2 | Heymsfield,XENDOS (Chiasson), | hospitalisation for heart failure | no data | All cause death | no data | TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
All type of patients: 28 trials - Bakris - Broom - Broom, - Davidson - Deerochanawong, - Derosa - Gotfredsen - Halpern - Hanefeld - Hauptman - Hill - Hollander - Karhunen - Kelley - Krempf - Lindgarde - Lucas - Micic - Miles - Muls - Naumov - Reaven - Rissanen - Rosenfalck - Rossner - Shi Yi - Sjostrom - Vidgren
Orlistat vs placebo | No demonstrated result | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
---|
weight loss equal to or greater than 5 percent | no data | weight loss equal to or greater than 10 percent | no data | cardiovascular events | no data | TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |